chemoresistance

che·mo·re·sis·tance

(kē'mō-rē-zis'tants),
The resistance of bacteria or malignant cells to the inhibiting action of certain chemical substances used in treatment.

chemoresistance

/che·mo·re·sis·tance/ (-re-zis´tans) specific resistance acquired by cells to the action of certain chemicals.

chemoresistance

1 a specific resistance by components of a cell to chemical substances.
2 the resistance of bacteria or a cancer cell to a chemical designed to treat the disorder.

chemoresistance

1. Resistance of cells to the action of a specific therapeutic agent.
2. Resistance of a particular tumor to chemotherapy; treatment refractory.

che·mo·re·sis·tance

(kē'mō-rē-zis'tăns)
The state of being resistant to a chemical.
References in periodicals archive ?
Glut-1 as a therapeutic target: increased chemoresistance and HIF-1-independent link with cell turnover is revealed through COMPARE analysis and metabolomic studies.
More recently, increasing evidence has indicated that the engagement of TLRs can promote cancer cell growth, induce evasion of immune surveillance, and enhance tumor metastasis and chemoresistance, or rather, induction of tumor cell apoptosis depending on ligands (Gonzalez-Reyes et al.
BRAF(V600E) inhibitors have led to clinically significant improvements in outcomes for melanoma patients, yet many patients with metastatic melanoma rapidly succumb to the disease due to eventual chemoresistance, or insensitivity to the drug.
Cystine-glutamate transporter SLC7A11 in cancer chemosensitivity and chemoresistance.
Epigenetics and chemoresistance in colorectal cancer: an opportunity for treatment tailoring and novel therapeutic strategies.
Expression of ERCC1, p53, and class III ,8-tubulin do not reveal chemoresistance in endometrial cancer: results from an immunohistochemical study.
STAT3 is constitutively active in most tumour cells and interestingly, its activation has been associated with chemoresistance and radioresistance.
One mechanism by which this opposition, commonly known as chemoresistance, happens is through the expression of drug transporter pumps in leukemia cells that actively pump out chemotherapeutics, including Daunorubicin.
There is a struggle in oncology over the use of chemosensitivity and chemoresistance testing: Can these tests produce better outcomes for patients?
Chemoprevention, chemotherapy, and chemoresistance in colorectal cancer.